Market research
RTRX Retrophin, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 31.38
- Dividend yield
- 0.0%
- Beta
- 0.72
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US7612991064
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 31.38
- Dividend yield
- 0.0%
- Beta
- 0.72
About
About Retrophin, Inc
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RTRX discussion.
5 years, 4 months ago
Travere Therapeutics, Inc is currently in a long term uptrend where the price is trading 38.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Travere Therapeutics, Inc's total revenue rose by 15.2% to $51M since the same quarter in the previous year.
Its net income has increased by 38.2% to $-23M since the same quarter in the previous year.
Finally, its free cash flow grew by 98.7% to $-180K since the same quarter in the previous year.
Based on the above factors, Travere Therapeutics, Inc gets an overall score of 5/5.